Journal: BMC Medical Genetics

Article Title: Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease

doi: 10.1186/1471-2350-11-36

Figure Lengend Snippet: Overview of location and type of the SNPs studied

Article Snippet: 3 , rs1048290 , 10461442 , C>G , Exon 4 , Synonymous , C___9323035_1_.

Techniques: TaqMan Assay, Sequencing

Journal: BMC Medical Genetics

Article Title: Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease

doi: 10.1186/1471-2350-11-36

Figure Lengend Snippet: Schematic overview of the NFE2L2 (panel A) and KEAP1 (panel B) genes and the tag SNPs used in the study (for rs-numbers see table 2) . Thick black lines indicate exons. The promoter region of NFE2L2 is detailed in panel A.

Article Snippet: 3 , rs1048290 , 10461442 , C>G , Exon 4 , Synonymous , C___9323035_1_.

Techniques:

Journal: BMC Medical Genetics

Article Title: Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease

doi: 10.1186/1471-2350-11-36

Figure Lengend Snippet: Single marker frequencies and associations with risk of PD

Article Snippet: 3 , rs1048290 , 10461442 , C>G , Exon 4 , Synonymous , C___9323035_1_.

Techniques: Marker, Control

Journal: BMC Medical Genetics

Article Title: Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease

doi: 10.1186/1471-2350-11-36

Figure Lengend Snippet: Haplotype frequencies in PD cases and controls

Article Snippet: 3 , rs1048290 , 10461442 , C>G , Exon 4 , Synonymous , C___9323035_1_.

Techniques: Control

Journal: The Journal of Biological Chemistry

Article Title: HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression

doi: 10.1074/jbc.RA118.007006

Figure Lengend Snippet: Class IIa HDAC catalytic domain inhibition does not stimulate NRF2 through KEAP1 inactivation. A and B, NRVMs were treated with vehicle control (DMSO, 0.1% final concentration), TMP195 (3 μm), or AI-1 (10 μm) for the indicated times. Hmox1 (A) and Srxn1 (B) mRNA levels were determined by qRT-PCR. Values represent means + S.E.; n = plates of cells/condition. *, p < 0.05 versus vehicle at the equivalent time. C, protein homogenates were prepared from NRVMs treated as described in A and subjected to immunoblotting with antibodies specific for NRF2 or α-tubulin (α-Tub). Veh, vehicle. D, NRVMs were treated for 36 h with compounds and vehicle control as described above. Protein homogenates were immunoblotted with antibodies against HMOX1; calnexin served as a loading control. E and F, primary rat aortic smooth muscle cells (E) and neonatal rat cardiac fibroblasts (F) were treated for 48 h with compounds and vehicle control as described above; Srxn1 mRNA expression was assessed by qRT-PCR. Values represent means + S.E. *, p < 0.05 versus vehicle. G, schematic of the in vitro assay to determine whether TMP195 covalently couples to KEAP1. H, the signals of unmodified tryptic peptides that contain KEAP1 Cys-151, which is a common site of electrophilic addition, were measured on an LTQ IonTrap following in vitro incubation of KEAP1 with vehicle control, TMP195, or AI-1; AI-1 served as a positive control. The LC peaks for the Cys-151–containing peptide are indicated by a black arrow; a reduced signal indicates that a compound conjugated to the peptide. The inset shows a side-by-side comparison of the peak for the Cys-151–containing peptide in the different treatment groups. I, the MS experiment in H was repeated to include three additional samples per treatment group. Relative abundance reflects the area under the curve normalized to the DMSO group. Values represent means + S.E. *, p < 0.05 versus DMSO-treated peptide.

Article Snippet: Plasmids The complementary DNA for human KEAP1 (a gift from Qing Zhong, Addgene plasmid 28023) was PCR-amplified using PFU Turbo DNA Polymerase (Agilent Technologies) and subcloned into pET28a to encode His 6 -tagged full-length hKEAP1.

Techniques: Inhibition, Control, Concentration Assay, Quantitative RT-PCR, Western Blot, Expressing, In Vitro, Incubation, Positive Control, Comparison